Myong-Jin Kim, PharmD, FCP
Director, Div of Therapeutic Performance II/ORS/OGD/CDER, US Food & Drug Administration
Dr. Kim became a Fellow of ACCP in 2017. Her ACCP activities include participation on the 2023 Annual Meeting Program Committee (2022 – present), the Honors & Awards Committee (2021 – 2022) and the Publications Committee (2017 – 2018). Dr. Kim has also served on the editorial board of The Journal of Clinical Pharmacology (JCP) since 2017 and has published 13 articles including the FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications”. In 2020, she served as the co-guest editor of the JCP Supplement Issue on Women’s Health (2020, Volume 60, Issue S2). She has attended the 2017, 2018, 2020 and 2021 ACCP Annual Meetings.